Fecal viral DNA shedding following clinical panleukopenia virus infection in shelter kittens: a prospective, observational study

Kyrsten J Janke¹, Linda S Jacobson¹*, Jolene A Giacinti² and J Scott Weese²*

Abstract

Objectives The aims of this study were to determine the magnitude and duration of fecal viral DNA shedding after diagnosis of feline panleukopenia (FP) in a group of shelter cats using quantitative real-time PCR (qPCR); to assess the utility of a negative point-of-care test or the resolution of diarrhea and systemic signs as proxy measures for qPCR positivity; and to investigate patterns of additional enteric pathogens in relation to feline panleukopenia viral shedding duration.

Methods Feline panleukopenia virus (FPV) infection in clinically affected shelter cats was confirmed by a commercial qPCR test. Observations were made on days 0, 3, 7, 14 and 21 post-diagnosis. Fecal flotation, FPV qPCR and the canine parvovirus IDEXX SNAP Parvo ELISA (SNAP) test were performed on fecal samples.

Results Forty cats and kittens with confirmed panleukopenia were initially enrolled. Sixteen kittens were sampled until day 14, and 12 were followed to day 21. Median DNA viral copy numbers fell below the diagnostic cut-off by day 7, with 13/16, 6/16, 1/16 and 0/12 testing PCR-positive on days 3, 7, 14 and 21, respectively. The SNAP test was positive in 12/16 kittens on day 0 and only 3/16 on day 3. SNAP test results, diarrhea and systemic signs were inconsistent in relation to qPCR positivity post-diagnosis. Additional enteric pathogens were common. The presence of additional pathogen types was suggestive of a longer PCR shedding duration, but this was not tested statistically owing to the small sample size.

Conclusions and relevance These findings suggest that cats should be isolated for at least 14 days after a diagnosis of FP, but that release from isolation after this point is reasonable, in association with a multifaceted infection control strategy. The study findings did not support using SNAP test results, diarrhea or systemic signs as proxy measures for virus shedding.

Keywords: Panleukopenia; parvovirus; virus-shedding; quantitative real-time PCR; isolation; point-of-care; animal shelter; quarantine

Accepted: 17 May 2021

Introduction

Feline panleukopenia virus (FPV), or feline parvovirus, is a highly transmissible pathogen that causes feline panleukopenia (FP), a severe vaccine-preventable illness of domestic cats.¹ Clinical infection is characterized by gastroenteritis, panleukopenia and septic shock.² FPV is shed in large quantities in saliva, urine, vomitus and feces, and can persist in an environment for up to a year.¹ It is transmitted primarily by the fecal-oral route, with fomite transmission playing an important role.¹,³ Animal shelters are at risk for outbreaks because of shifting populations derived from multiple sources, intake of unvaccinated adults and vulnerable kittens, environmental persistence of the virus and fomite transmission.⁴,⁵ Outbreaks can result in high mortality, euthanasia and shelter closures.²,⁶,⁷

¹Toronto Humane Society, Toronto, Canada
²Ontario Veterinary College, Guelph, Canada

Corresponding author:
Linda S Jacobson BVSc, MMedVet(Med), PhD, Toronto Humane Society, 11 River St, Toronto, Ontario M5A 4C2, Canada
Email: ljacobson@torontohumanesociety.com
The isolation of infected animals is essential to prevent disease transmission within shelters, but prolonged isolation has implications for shelter capacity, animal welfare, kitten socialization and length of stay before adoption. The required isolation period is dependent on the expected duration and magnitude of pathogen shedding following infection. Reviews and book chapters report that typical FPV shedding duration in cats is 1–2 or 5–7 days, but shedding persisted for up to 6 weeks in one cat in an early study.

Previous shedding studies have primarily included experimentally infected cats in controlled environments. In contrast to these study populations, shelter settings frequently include large numbers of un- or under-vaccinated kittens, higher stress levels and a variety of enteric pathogens. These factors might influence the magnitude and/or duration of FPV shedding.

Shelters may use a combination of repeat testing, recommended time frames or resolution of clinical signs to determine the appropriate duration of isolation. Point-of-care (POC) tests can lack sensitivity, and while FPV PCR is highly sensitive, it is slow and expensive for routine use. It is of interest to shelters to assess whether proxy measures for reduced virus shedding, such as resolution of diarrhea and systemic signs, or a negative POC test, could be used to determine the appropriate timing for release from isolation.

The objectives of this study were to determine the magnitude and duration of fecal viral DNA shedding after diagnosis of FP in a group of shelter cats; assess the utility of a negative POC test or the resolution of diarrhea and systemic signs as proxy measures for viral DNA copy numbers present in fecal samples; and investigate patterns of additional enteric pathogens in relation to the duration of FPV shedding.

**Materials and methods**

**Institutional approval**

This observational study was approved by the chief executive officer of the shelter.

**Setting**

The study was performed at the Toronto Humane Society, a private, limited-admission shelter in Ontario, Canada. Cats were housed singly, in family groups or – in the case of orphan singleton kittens – co-housed with kittens of similar size and weight. The shelter admits animals through owner relinquishment, stray intake and rescue transport, and has a full-service veterinary hospital. FP is seen with some regularity, although case numbers are low (the average in 2019, for locally surrendered cats, was 2.3 cases per month). It is more likely to occur during the spring and summer when large numbers of juveniles are admitted. Shelter-acquired infections are unusual. Based on shelter metrics most cases are diagnosed soon after intake, within the incubation period, and then isolated. Exposed animals are traced and quarantined. Stringent infection control measures are routinely followed in the shelter. Affected cats are regularly transferred from other shelters that lack the resources to treat the disease.

At intake, cats ≥4 weeks of age were vaccinated with a modified live subcutaneous feline viral rhinotracheitis, feline calcivirus and feline panleukopenia virus (FVRCP) vaccine. Kittens were revaccinated every 2–3 weeks based on current recommendations. Further standardized intake procedures included examination by a veterinarian or registered veterinary technician; treatment with selamectin, pyrantel (all) and ponazuril (kittens); Wood’s lamp and retroviral screening; and rabies vaccination for cats ≥12 weeks of age. Pyrantel was repeated after 2 weeks and continued every 2–3 weeks for kittens. Additional diagnostics and treatment were provided as needed. Blood smears and complete blood counts were not routinely performed because leukopenia is transient and does not occur in all cases.

**Case definition and qPCR test**

Shelter cats with confirmed FPV infection, and for which follow-up testing was possible, were included in the study. The case definition for FPV infection was compatible clinical signs as described below and a positive FPV quantitative real-time (qPCR) test on a fecal sample or rectal swab.

Clinical criteria for FP were: (1) dehydration, obtundation to coma, hypothermia or hypoglycemia; or, in adult cats (2) anorexia/hyporexia and lethargy in association with vomiting and/or diarrhea; or, in kittens (3) anorexia/hyporexia, lethargy and weight loss, or diarrhea with or without additional signs, or vomiting with anorexia/hyporexia or pyrexia.

Diarrhea was defined as stool score of 5–7 using the Purina Veterinary Diets Fecal Scoring Chart (http://vhc.missouri.edu/wp-content/uploads/2020/07/Nestle-Purina-Fecal-Scoring-System.pdf).

A commercial qPCR test was used (IDEXX Reference Laboratories). The qPCR targeted the FP VP2 gene EU252145, and was able to detect both FPV and canine parvovirus (CPV). The analytic sensitivity was 10 DNA copies/reaction. The reference laboratory defined a positive diagnosis as cycle threshold (Ct) value of ≤26, which corresponded to ≥1.59 × 10⁶ (1,588,799) viral DNA copies per gram (EA Chan, IDEXX Reference Laboratories, personal communication). Ct values were converted to DNA viral copy numbers by the laboratory, using a proprietary calculation.

**Sample collection and monitoring**

Following confirmation of FPV infection (day 0), fecal samples were collected on days 3, 7, 14 and 21. Cats were made available for foster or adoption once sufficiently recovered. Information regarding potential shedding and the protection of resident cats was always provided. Fecal samples were collected in the shelter or in the homes of foster volunteers or adopters who opted in. Cats were
excluded if fecal samples could not be obtained on days 3, 7 and 14. Systemic signs (pyrexia, lethargy, anorexia/hyporexia and/or weight loss) were recorded, when possible, on the days of sample collection.

Sample handling and testing
Initial diagnostic samples were processed immediately. Samples from recovering cats were processed immediately or stored at –20°C for up to 60 days. All samples were tested with the IDEXX SNAP Parvo ELISA (SNAP) test and the Diarrhea RealPCR Panel (Comprehensive). Pathogens included in the panel were Campylobacter species, Clostridium perfringens, Cryptosporidium species, feline enteric coronavirus, Salmonella species, Toxoplasma gondii and Tritrichomonas foetus. Additional enteric pathogens were identified by in-house fecal flotation using zinc sulfate centrifugation at intake or as requested by medical staff. The total number of additional pathogens was reported for each kitten, regardless of at which time point(s) they were detected. SNAP tests were performed by a trained research assistant, according to the manufacturer’s instructions. qPCR tests were performed by the reference laboratory.

Data analysis
Descriptive statistics were generated using Microsoft Excel. The presence/absence of diarrhea and systemic signs were reported as proportions as data were not available for all cats after day 7, following fostering or adoption. The duration of viral shedding was described in relation to the number and type of additional enteric pathogens identified by fecal flotation and qPCR.

Results
Forty cats and kittens with confirmed FPV infection were enrolled; their median age was 5 weeks (interquartile range [IQR] 4–8; range 2–104); 3/40 cats were >20 weeks of age. Thirty-two of the 40 (80%) cats survived the infection and were subsequently adopted. Eight cats died or were euthanized before 14 days post-diagnosis. One or more samples were missing for 16 cats because of relocation to foster or adoptive homes. Full data sets to day 14 were available for 16 cats, all of which were kittens (median age 5 weeks; range 2–8).

The day of the first positive qPCR test was designated as day 0. Sixteen kittens were followed for 14 days from day 0, and 12 of these were followed for 21 days. On day 0 no kittens were pyrexic, 75.0% had diarrhea, 68.8% had weight loss and 25.0% had vomiting. The qPCR test was positive at the time of onset of clinical signs in 12 cases. For the remaining four kittens, the qPCR was initially negative, but was positive on repeat testing 4 days later (day 0). The median DNA viral copy number (per gram of feces) on initial testing for these four cats was $2.88 \times 10^5$ (IQR $2.55 \times 10^4$–$6.97 \times 10^5$). This increased to $7.53 \times 10^6$ (IQR $2.30 \times 10^4$–$8.74 \times 10^9$) on repeat testing.

On day 3, 13/16 (81.3%) kittens remained qPCR positive, while only 3/16 (18.8%) had positive SNAP tests (Table 1). Six of 16 (37.5%) kittens tested qPCR positive on day 7, and no SNAP tests were positive at this time point. There was one positive qPCR test on day 14, and one weak positive SNAP test from a different kitten that was qPCR negative. All other SNAP tests for this kitten were negative. On day 21, no samples tested positive on either test. Other than the weak positive SNAP result on day 14, there was no instance in which either type of test was positive following a negative result.

The median viral DNA viral copy number at day 0 was $5.00 \times 10^8$ (IQR $9.59 \times 10^7$–$5.17 \times 10^9$), falling to $5.66 \times 10^6$ (IQR $2.00 \times 10^6$–$3.18 \times 10^8$) on day 3 (Figure 1; see also the

![Figure 1](image-url) DNA viral copy counts in fecal samples from recovering shelter kittens after a diagnosis of clinical feline panleukopenia virus (FPV) infection by quantitative real-time PCR (n = 16 to day 14; n = 12 at day 21). Dotted line = median DNA copy counts
Median counts fell below the positive diagnostic cut-off of $1.59 \times 10^6$ viral DNA copies by day 7.

The proportion of kittens with diarrhea at the five time points was 75.0%, 87.5%, 43.8%, 56.3% and 18.2%, respectively (Figure 2, Table 2). Kittens with diarrhea were frequently qPCR-negative. On day 14, the single qPCR-positive kitten did not have diarrhea, while 9/15 (60.0%) qPCR-negative cats had diarrhea. The proportion with diarrhea was greater than the proportion with positive qPCR tests at all time points except day 0, and diverged most at day 14, where 6.3% had positive qPCR tests and 56.3% had diarrhea (Figure 2). The presence or absence of systemic signs (pyrexia, lethargy, anorexia/hyporexia or weight loss) was recorded for 16 kittens on days 0 and 3, 13 kittens on days 7 and 14, and nine kittens on day 21. On day 0, 75.0% of kittens had both systemic signs and a positive qPCR test, compared with 68.8% on day 3 and 0.0% at the subsequent time points (Figure 2, Table 2). On days 7 and 14, systemic signs were absent in all qPCR-positive cats and present in 28.6% (day 7) and 16.7% (day 14) of qPCR-negative cats.

At least one additional enteric pathogen was detected in 14/16 (87.5%) kittens during the study period (Table 2). Eleven had a single additional pathogen (Iospora felis $n = 4$, C. perfringens $n = 4$, feline enteric coronavirus $n = 3$) and three had two additional pathogens – feline enteric coronavirus, and either C. perfringens or T. catti. Neither of the kittens with no additional enteric pathogens ($n = 2$) tested qPCR positive on day 7, while 3/11 kittens with one additional enteric pathogen and 3/3 kittens with two additional pathogens tested qPCR positive on day 7. Those with one additional enteric pathogen all tested qPCR negative by day 14 and all those with two additional enteric pathogens were negative at day 14.

Table 2: Diarrhea, systemic signs (pyrexia, lethargy, anorexia/hyporexia and/or weight loss) and additional enteric pathogens (AEPs)* in relation to quantitative real-time PCR (qPCR) test results in shelter kittens with clinical feline panleukopenia virus infection

| Sample size | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 |
|-------------|-------|-------|-------|--------|--------|
| qPCR positive | Diarrhea | 12 | 11 | 3 | 0 |
| No diarrhea | 4 | 2 | 3 | 1 | 0 |
| qPCR negative | Diarrhea | 0 | 3 | 4 | 9 |
| No diarrhea | 0 | 0 | 6 | 6 | 9 |

Table 2 (continued)

| Sample size | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 |
|-------------|-------|-------|-------|--------|--------|
| qPCR positive | Systemic signs | 12 | 11 | 0 | 0 |
| No systemic signs | 4 | 2 | 6 | 1 | 0 |
| qPCR negative | Systemic signs | 0 | 2 | 2 | 1 |
| No systemic signs | 0 | 1 | 5 | 10 | 8 |

| Sample size | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 |
|-------------|-------|-------|-------|--------|--------|
| qPCR positive | No AEPs | 2 | 1 | 0 | 0 |
| One AEP | 11 | 9 | 3 | 0 | 0 |
| Two AEPs | 3 | 3 | 3 | 1 | 0 |
| qPCR negative | No AEPs | 0 | 1 | 2 | 2 |
| One AEP | 0 | 2 | 8 | 11 | 9 |
| Two AEPs | 0 | 0 | 0 | 2 | 1 |

*Identified by fecal flotation or qPCR panel (Campylobacter species, Cryptosporidium species, feline enteric coronavirus, Salmonella species, Toxoplasma gondii and Tritrichomonas foetus)

†One sample could not be scored due to damage in transit
21 days. Kittens that were positive beyond day 3 had *T cati* (n = 2), feline enteric coronavirus (n = 4) or *C perfringens* infection (n = 3). The kitten that was positive on day 14 was positive for *T cati* and feline enteric coronavirus.

**Discussion**

In this study, only 1/16 kittens with panleukopenia were qPCR positive at 14 days post-diagnosis, and 0/12 kittens were positive at day 21. The single weak-positive SNAP test at day 14 was most likely a false positive, as this sample was qPCR negative and the kitten had no other positive SNAP test results.

The IDEXX technical cut-off for the FPV qPCR test is based on viral DNA copy numbers considered to be clinically significant (MA Seguin, IDEXX Reference Laboratories, personal communication). However, the precise threshold required for disease transmission is unknown. Infective doses are typically expressed as TCID$_{50}$, which indicates the amount of virus required to produce a cytopathic effect in 50% of inoculated tissue culture cells.$^{21}$ It is not possible to relate this directly to viral DNA copy numbers, mainly because PCR amplifies nucleic acid from both viable and non-viable virus,$^{22}$ while TCID$_{50}$ measures an effect that is produced only by biologically active virus. Recent studies of SARS-CoV-2$^{23,24}$ serve as an important reminder that PCR-detectable virus cannot be extrapolated to be viable virus. Similarly, other human respiratory viruses showed a clear pattern of positive qPCR results persisting beyond the point that virus could be cultured.$^{25}$ In the current study, virus DNA remained detectable at low copy numbers in 11/12 kittens at day 21 (Figure 1; see also the table in the supplementary material). Low residual copy numbers are unsurprising when using highly sensitive test modalities such as qPCR.

There is little previously published information about the clinical shedding period for FPV. In an older study using virus isolation, FPV was isolated from the feces of 3/4 cats at days 20–22 post-infection; 0/13 cats at days 27–36; 1/10 cats at days 41–43; and 0/16 cats at days 48–120.$^{9}$ In a qPCR study, median DNA viral copy numbers in experimentally infected cats peaked at day 6 post-infection and decreased to low levels (mean count < 6.5 × 10$^4$ copies/sample) by day 12.$^{10}$ Our results showed a similar pattern over time, after taking into account that day 0 of the current study was the day of diagnosis, not of infection (see Figure 1).

More data are available for CPV, which, like FPV, is a carnivore protoparvovirus,$^{1}$ with very little genetic variation from FPV.$^{18}$ In puppies with parvovirus infection, CPV was detectable by PCR for a median of 46 days post-infection.$^{22}$ For the reasons provided above, it is important to distinguish between detectable and clinically significant viral loads. Median counts in these puppies were consistently low after day 15 post-infection,$^{22}$ with a similar pattern to our study. In contrast to prolonged low viral DNA counts using qPCR, studies using viral isolation found that viable CPV was shed only briefly, for a maximum of 8–14 days post-infection.$^{22,26–30}$ This time period corresponded with peak viral DNA copy numbers in PCR studies of FPV and CPV,$^{10,22}$ and is consistent with findings in the current study. It is unknown if the single cat that shed viable virus (positive on culture) on days 41–43 in an older study$^9$ represents an anomaly or a more frequent event, but available data suggest that the former may be the case.

Release of infected animals from isolation requires reasonable assurance that the released animal will not be contagious, and is therefore based on knowledge of typical shedding times. The main limitation of PCR as a means to determine shedding duration is its detection of non-viable virus. However, these more conservative results may act as a safety net, to avoid early release of cats with longer shedding durations that have not been captured in the relatively small body of literature. Our study showed consistently negative qPCR results following the first negative result, demonstrating that intermittent, clinically significant, shedding did not occur in this study.

The study findings did not support using a negative SNAP test or resolution of diarrhea or systemic signs (pyrexia, lethargy, inappetance and/or weight loss) as a means to determine when to release a recuperating animal from isolation. These measures were inconsistent in relation to qPCR, the reference standard, and were therefore unreliable proxy measures. Determining the duration of isolation based on these measures would have resulted in premature release from isolation in some cases and delayed release in others. As has been mentioned,$^5$ diarrhea was not reliably present at the time of FPV diagnosis in our study. The later presence of diarrhea in a substantial proportion of cats that tested qPCR negative was most likely from a combination of intestinal damage and intestinal microbiota disruption from FPV, additional enteric pathogens, shelter stress and diet changes, including weaning.

Previous shelter recommendations were to hold recovered cats for 3 weeks after *recovery,*$^{14}$ while more recent recommendations were to isolate for 4 weeks after *diagnosis,*$^{15}$ this can take place in an adoptive or foster home. The results of this and previous studies suggest that clinically significant shedding is unlikely to occur beyond 14 days after diagnosis in the majority of animals, and that release from isolation after this point is reasonable. Biological variation means that some risk upon release at this time point is unavoidable. A multifaceted approach of vaccination upon intake, cohorting, robust cleaning and disinfection protocols, and strategic placement of recovered cats (directly to foster or adoptive homes, or in adoption rooms containing fully vaccinated adults) is required to concurrently avoid prolonged isolation time and minimize risks upon release from isolation. The use of PCR testing could accelerate release from isolation in
some cases but has the disadvantages of cost, time delay and the need for more than one pre-release test in animals that are initially positive on retesting.

The majority of kittens in our study had additional enteric pathogens, which could have prolonged the duration of diarrhea and PCR positivity. Additional enteric pathogens are common in shelter cats.12,13 Coinfections may have synergistic or antagonistic interactions with viruses, facilitating or competing with their establishment.31 In a study of Giardia species and CPV coinfections in three dogs, giardiasis was associated with more severe clinical signs but did not appear to impact CPV shedding duration.27 Although the sample size in our study was small and statistical analysis was not performed, the maximum FPV shedding duration of cats with additional enteric pathogens increased with the number of enteric pathogens present. Further studies with larger sample sizes would be necessary to clarify this relationship.

While not the focus of the study, the survival rate of 80% for the 40 cats that met the FP case definition is noteworthy, and contrasts with previously reported mortality of 50–90%.1,2,6,7 This may reflect the medical care and resources available to the shelter, in particular the ability to provide intravenous fluids and medications to very small kittens.

The study had several limitations, the most important of which were the small sample size, the lack of sampling between 14 and 21 days, and the unknown virus viability at the time points following diagnosis. The study was performed in field conditions, in which many variables cannot be controlled. However, these conditions more closely reflect the realities faced by shelters. Larger sample sizes and a study design that includes virus isolation would provide valuable additional information.

**Conclusions**
The study findings and previous literature suggest that kittens recovering from FPV infection should be isolated for at least 14 days after diagnosis. Release from isolation after this point appears to be reasonable, in association with a multifaceted infection control strategy. The study findings did not support using diarrhea, systemic signs or SNAP test results as proxy measures for virus shedding.

**Acknowledgements** With grateful thanks to Toronto Humane Society leadership and staff, and to Dr Roxanne Chan, Dr Christian Leutenegger and Gina Lockwood for their invaluable advice and assistance. The authors gratefully acknowledge EveryCat Health Foundation (formerly the Winn Feline Foundation), PetSmart Charities and IDEXX Laboratories for their generous support.

**Supplementary material** The following file is available online:
Supplementary table: SNAP and PCR test results for 16 kittens with clinical feline panleukopenia virus infection.

**Conflict of interest** The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding** EveryCat Health Foundation, in collaboration with PetSmart Charities, provided funding for grants with special emphasis in feline shelter medicine (grant W19-003). IDEXX Laboratories Canada provided complimentary qPCR testing.

**Ethical approval** The work described in this manuscript involved the use of non-experimental (owned or unowned) animals. Established internationally recognized high standards (‘best practice’) of veterinary clinical care for the individual patient were always followed and/or this work involved the use of cadavers. Ethical approval from a committee was therefore not specifically required for publication in *JFMS*. Although not required, where ethical approval was still obtained, it is stated in the manuscript.

**Informed consent** Informed consent (verbal or written) was obtained from the owner or legal custodian of all animal(s) described in this work (experimental or non-experimental animals, including cadavers) for all procedure(s) undertaken (prospective or retrospective studies). No animals or people are identifiable within this publication, and therefore additional informed consent for publication was not required.

**ORCID ID** Linda S Jacobson https://orcid.org/0000-0001-9704-8737
J Scott Weese https://orcid.org/0000-0003-1896-1937

**References**
1. Barrs VR. Feline panleukopenia: a re-emergent disease. *Vet Clin North Am Small Anim Pract* 2019; 49: 651–670.
2. Kruse BD, Unterer S, Horlacher K, et al. Prognostic factors in cats with feline panleukopenia. *J Vet Intern Med* 2010; 24: 1271–1276.
3. Csiza CK, De Lahunta A, Scott FW, et al. Pathogenesis of feline panleukopenia virus in susceptible newborn kittens I. Clinical signs, hematology, serology, and virology. *Infect Immun* 1971; 3: 833–837.
4. Sykes JE. Feline panleukopenia virus infection and other viral enteritides. In: Sykes J (ed). Canine and feline infectious diseases. Philadelphia, PA: Elsevier Saunders, 2013, pp 187–194.
5. Greene CE. Feline enteric viral infections. In: Greene C (ed). Infectious diseases of the dog and cat. St Louis, MO: Elsevier Saunders, 2012, pp 80–91.
6. Litster A and Benjanirut C. *Case series of feline panleukopenia virus in an animal shelter*. *J Feline Med Surg* 2014; 16: 346–353.
7. Porporato F, Horzinek MC, Hofmann-Lehmann R, et al. Survival estimates and outcome predictors for shelter cats with feline panleukopenia virus infection. *J Am Vet Med Assoc* 2018; 253: 188–195.
8. Newbury S, Blinn MK, Bushby PA, et al. *Guidelines for standards of care in animal shelters*. https://www.sheltervet.org/assets/docs/shelter-standards-oct2011-wforsward.pdf (2010; accessed May 25, 2021).
9. Csiza CK, Scott FW, de Lahunta A, et al. Immune carrier state of feline panleukopenia virus-infected cats. *Am J Vet Res* 1971; 32: 419–426.

10. Jas D, Aebeler C, Lacombe V, et al. Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline panleukopenia, feline calicivirus and feline herpesvirus. *Vet J* 2009; 182: 86–93.

11. Kry K and Casey R. The effect of hiding enrichment on stress levels and behaviour of domestic cats (*Felis silvestris catus*) in a shelter setting and the implications for adoption potential. *Anim Welf* 2007; 16: 375–383.

12. Andersen LA, Levy JK, McManus CM, et al. Prevalence of enteropathogens in cats with and without diarrhea in four different management models for unowned cats in the southeast United States. *Vet J* 2018; 236: 49–55.

13. Sabshin SJ, Levy JK, Tupler T, et al. Enteropathogens identified in cats entering a Florida animal shelter with normal feces or diarrhea. *J Am Vet Med Assoc* 2012; 241: 331–337.

14. Tuzio H. Feline panleukopenia. In: Hurley KF and Miller L (eds). Infectious disease management in animal shelters. Ames, IA: Wiley-Blackwell, 2009, pp 183–196.

15. Guidebook: Feline panleukopenia. https://www.sheltermedicine.com/library/guidebooks/?r=feline-panleukopenia (2017, accessed September 15, 2020).

16. Neuerer FF, Horlacher K, Truyen U, et al. Comparison of different in-house test systems to detect parvovirus in faeces of cats. *J Feline Med Surg* 2008; 10: 247–251.

17. Jacobson LS, Janke K, Giacinti JA, et al. Diagnostic testing for feline panleukopenia in a shelter setting: a prospective, observational study. *J Feline Med Surg*, Epub ahead of print 13 April 2021. DOI: 10.1177/1098612X211005301.

18. Abd-Eldaim M, Beall MJ and Kennedy MA. Detection of feline panleukopenia virus using a commercial ELISA for canine parvovirus. *Vet Ther* 2009; 10: E1–E6.

19. DiGangi BA, Levy JK, Reese MJ, et al. Effects of maternally-derived antibodies on serologic responses to vaccination in kittens. *J Feline Med Surg* 2012; 14: 118–123.

20. Stone AES, Brummet GO, Carozza EM, et al. 2020 AAHA/AAFP Feline Vaccination Guidelines. *J Am Anim Hosp Assoc* 2020; 56: 249–265.

21. Timeless TCID50: One solution to many viruses. https://virologyresearchservices.com/2019/03/29/timeless-tcid50-one-solution-to-many-viruses/ (2019, accessed 28 January 2021).

22. Decaro N, Desario C, Campolo M, et al. Clinical and virological findings in pups naturally infected by canine parvovirus type 2 Glu-426 mutant. *J Vet Diagnostic Investig* 2005; 17: 133–138.

23. Ben-Shmuel A, Brosh-Nissimov T, Glinert I, et al. Detection and infectivity potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental contamination in isolation units and quarantine facilities. *Clin Microbiol Infect* 2020; 26: 1658–1662.

24. Mondelli MU, Colaneri M, Seminari EM, et al. Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. *Lancet Infect Dis* 2021; 21: e112.

25. Richardson L, Brite J, Del Castillo M, et al. Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy. *Clin Microbiol Infect* 2016; 22: 380. e1–380.e7.

26. Potgieter L, Jones J, Patton C, et al. Experimental canine parvovirus infection in dogs. *Can J Comp Med* 1981; 45: 212–216.

27. Pollock R. Experimental canine parvovirus infection in dogs. *Cornell Vet* 1982; 72: 103–119.

28. Carman S and Powey C. Successful experimental challenge of dogs with canine parvovirus-2. *Can J Comp Med* 1982; 46: 33–38.

29. Proksch AL, Unterer S, Speck S, et al. Influence of clinical and laboratory variables on faecal antigen ELISA results in dogs with canine parvovirus infection. *Vet J* 2015; 204: 304–308.

30. Meunier PC, Cooper BJ, Appel MJ, et al. Pathogenesis of canine parvovirus enteritis: the importance of viremia. *Vet Pathol* 1985; 22: 60–71.

31. Vaumourin E, Vourc’h G, Gasqui P, et al. The importance of multiparasitism: examining the consequences of co-infections for human and animal health. *Parasit Vectors* 2015; 8: 545. DOI: 10.1186/s13071-015-1167-9.